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BACKGROUND: Pediatric cardiomyopathy is a genetically heterogeneous disease with substantial morbidity and mortality.
Current guidelines recommend genetic testing in children with hypertrophic, dilated, or restrictive cardiomyopathy, but practice variations exist. Robust data on clinical testing practices and diagnostic yield in children are lacking. This study aimed to
identify the genetic causes of cardiomyopathy in children and to investigate clinical genetic testing practices.
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METHODS AND RESULTS: Children with familial or idiopathic cardiomyopathy were enrolled from 14 institutions in North America.
Probands underwent exome sequencing. Rare sequence variants in 37 known cardiomyopathy genes were assessed for
pathogenicity using consensus clinical interpretation guidelines. Of the 152 enrolled probands, 41% had a family history of
cardiomyopathy. Of 81 (53%) who had undergone clinical genetic testing for cardiomyopathy before enrollment, 39 (48%)
had a positive result. Genetic testing rates varied from 0% to 97% between sites. A positive family history and hypertrophic
cardiomyopathy subtype were associated with increased likelihood of genetic testing (P=0.005 and P=0.03, respectively). A
molecular cause was identified in an additional 21% of the 63 children who did not undergo clinical testing, with positive results
identified in both familial and idiopathic cases and across all phenotypic subtypes.
CONCLUSIONS: A definitive molecular genetic diagnosis can be made in a substantial proportion of children for whom the cause and
heritable nature of their cardiomyopathy was previously unknown. Practice variations in genetic testing are great and should be
reduced. Improvements can be made in comprehensive cardiac screening and predictive genetic testing in first-degree relatives.
Overall, our results support use of routine genetic testing in cases of both familial and idiopathic cardiomyopathy.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01873963.
Key Words: exome ■ heart failure ■ infant ■ molecular ■ mutation

C

ardiomyopathy is a clinically and genetically heterogeneous form of heart muscle disease with
substantial morbidity and mortality in children.

There are 5 phenotypes: hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive
cardiomyopathy (RCM), left ventricular noncompaction
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CLINICAL PERSPECTIVE
What Is New?

• There is significant practice variation in ordering genetic testing for pediatric patients with
cardiomyopathy.
• In a pediatric cardiomyopathy cohort in which
≈50% had clinical genetic testing, 21% of nontested patients had a diagnostic genetic finding
with research-based testing of known cardiomyopathy genes.

What Are the Clinical Implications?

• Routine use of genetic testing in children with familial or idiopathic cardiomyopathy is indicated.

Nonstandard Abbreviations and Acronyms
DCM
HCM
LVNC
PCMR
RCM
VUS

dilated cardiomyopathy
hypertrophic cardiomyopathy
left ventricular noncompaction
pediatric cardiomyopathy registry
restrictive cardiomyopathy
variant of uncertain significance
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cardiomyopathy (LVNC), and arrhythmogenic ventricular cardiomyopathy.1 Current consensus guidelines
recommend genetic testing in children and adults
with cardiomyopathy. Cardiac surveillance is recommended in first-degree relatives, and genetic testing
for a known familial variant is indicated.2-4 Despite
these recommendations, financial factors related to
reimbursement, the family’s understanding and perception of genetic testing, and limited data to guide
physician practice with respect to pediatric cardiomyopathies are all barriers to genetic testing. In addition,
variations in genetic testing practices in this age group
are not well studied.5
Epidemiologic studies indicate that although the
causes of cardiomyopathy in children are more diverse than in adults,6-8 genes encoding sarcomeric,
cytoskeletal, or desmosomal proteins are important causes of cardiomyopathy across all ages.9-13
However, data regarding the diagnostic yield of genetic testing in children with cardiomyopathy are limited and conflicting. For example, molecular analysis
in children with HCM at a single institution found
a higher prevalence of pathogenic variants than
in adults,14 but results from a large clinical genetic
testing laboratory found a lower prevalence.15 Case
reports have prompted speculation that children

with ≥2 pathogenic variants may have early-onset
severe disease. A recent retrospective review of
sarcomeric mutation carriers showed that 25% of
patients <18 years of age had ≥2 pathogenic or likely
pathogenic variants (versus 4.8% for adults), but the
number of children was small (n=24) and potentially
confounded by ascertainment bias.16 The frequency
of 2 mutations in adults with HCM was recently
found to be much lower than previously indicated.17
Conflicting literature on genetic findings may contribute to practice variation in the genetic evaluation of
children with cardiomyopathy.
Two centers have recently published retrospective
evaluations of their patients with pediatric cardiomyopathy who underwent clinical genetic testing,18,19
identifying a diagnostic yield of 26% in 151 pediatric
patients with mixed cardiomyopathy types19 and 40%
in 70 patients without HCM.18 Patients with pediatric
cardiomyopathy who did not undergo clinical testing
were not included. In a 2020 retrospective analysis of
clinical genetic testing in pediatric patients with DCM
(n=73) at a single institution from 2008 to 2018, 86%
underwent clinical genetic testing, with 30% having
positive findings and a high de novo variant rate.20
A recent prospective study in 60 pediatric patients
with all types of cardiomyopathy provided excellent
information on clinical outcome and interrogated 89
genes but considered variants of uncertain significance (VUSs), likely pathogenic, and pathogenic variants all as positive genetic findings.21 These studies
identified challenges inherent in the study of pediatric
cardiomyopathy such as the small patient numbers
at a single institution and lack of comprehensive
genetic evaluation or testing. We therefore initiated
the PCM Genes (Pediatric Cardiomyopathy Genes
study) to perform exome sequencing in a large prospectively recruited cohort. The overall goals of the
study are to develop approaches to exome analysis for autosomal dominant disease, to determine
genotype-
phenotype correlations and to identify
genetic modifiers that influence the long-term clinical course of children with cardiomyopathy. Here,
we present the first results of the study, in which we
determine the prevalence of pathogenic variants in
known cardiomyopathy genes; investigate the associations between phenotype and age of onset, sex,
race, and ethnic correlates; and identify practice variation in genetic testing of these children.

METHODS
Study Design
The study used the network established by the
PCMR (Pediatric Cardiomyopathy Registry).22,23
The University of Miami (2012–
2014), Wayne State
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University (2014–2018), and the University at Buffalo
(2018–2020) served as the Administrative Coordinating
Centers, which were responsible for regulatory and
clinical adherence, study implementation, protocol
guidance, data collection (Appendix S1), and analysis
planning. The New England Research Institute was the
Data and Statistical Coordinating Center. Cincinnati
Children’s Hospital Medical Center (2012–
2014) and
Indiana University (2014–
2020) served as Genetic
Coordinating Centers. All analytic and study materials
are available within this article and its online supplementary files. Deidentified genomic data will be publicly available within the database of Genotypes and
Phenotypes.

Patients
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Enrollment for the study began April 12, 2013 and
continued through February 29, 2016. Children were
eligible if they had a diagnosis of idiopathic or primary
cardiomyopathy with a phenotype of DCM, HCM, RCM,
or LVNC or presumed myocarditis before 18 years of
age. Diagnoses were ascertained by chart review and
confirmed by echocardiography (Table S1) or cardiac
magnetic resonance imaging. Children with cardiomyopathy secondary to another condition such as neuromuscular disease or a genetic syndrome associated
with cardiomyopathy were excluded (Table S2).
Biological parents and affected siblings or relatives
were approached for enrollment. After written informed
consent or assent, blood was drawn for genetic testing and a 3-generation pedigree was obtained. Saliva
samples were collected when blood collection failed.
A positive family history was defined as at least 1 additional biological family member with a diagnosis of
cardiomyopathy or with positive genetic testing results
for cardiomyopathy if phenotype negative. If clinical
genetic testing was already performed, results from
the testing laboratory were uploaded to the database.
All clinical genetic results were manually reviewed.
For this report, clinical genetic testing refers to
molecular testing for cardiomyopathy, typically with a
next-
generation sequencing cardiomyopathy panel;
other types of clinical genetic testing, such as chromosomes, were excluded.
Cardiac phenotypic data were collected for 3 years
before enrollment until 2 years after unless the child
died, underwent heart transplant, or withdrew from the
study. Data collected at study visits included demographic information, anthropometric measurements,
family history with pedigree, eligibility data, heart failure
class, the results of cardiac studies (echocardiograms,
cardiac magnetic resonance imaging, ECGs, Holter
monitoring, and endomyocardial biopsies), hospitalizations, cardiac transplant status, and cause of death.
Study data were entered into a web-based eClinicalOS
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system through dedicated, password-protected study
computers. The Institutional Review Boards at the
Administrative Coordinating Center and participating
institutions approved this study.

Sample Collection, Preparation, and
Sequencing
Blood or saliva samples were collected at each site
and shipped to the Genetic Coordinating Center.
DNA was extracted on a Maxwell RSC instrument
(Promega, Madison, WI) according to the manufacturer’s protocol. Exome sequencing was performed using
sequence capture (SeqCap EZ Human Exome 2.0;
Nimblegen, Madison, WI) and a HiSeq2500 sequencer
(Illumina, San Diego, CA) at Cincinnati Children’s
Hospital Medical Center in a Clinical Laboratory
Improvement Amendments–approved lab. All samples
were sequenced to a mean coverage of 72× (36× to
148×) (Table S3). Alignment was performed to Genome
Reference Consortium Human Build 37 GRCh37 with
BWA aln/sampe version 0.5.9 using default parameters. Genome Analysis Toolkit version 3.3 best practices were followed for variant calling,24 and variants
were annotated using a Cincinnati Children’s Hospital
Medical Center in-house script, according to their predicted impact on University of California–Santa Cruz
Known Genes (hg19).

Variant Assessment
At study initiation, 37 genes from clinical cardiomyopathy genetic testing panels were selected for interrogation (Table 1). These genes were selected at study
initiation based on panels that were orderable from
commercial clinical laboratories. In addition, they had
been shown clinically or in research testing in children
to cause disease. The one exception was the TTR gene,
which is not associated with cardiomyopathy in children
but was included as a potential modifier. Results were
returned to participants for all genes (n=36) except TTR
if return of results was elected upon consent. Among
Table 1. Cardiomyopathy-Causing Genes Analyzed in the
Pediatric Cardiomyopathy Genes Study
ABCC9

LAMP2

NEXN

ACTC1

LDB3

PLN

TNNI3

ACTN2

LMNA

PRKAG2

TNNT2

ANKRD1

TNNC1

MYBPC3

RBM20

TPM1

BAG3

MYH6

SCN5A

TTN

CAV3

MYH7

SCO2

TTR

CRYAB

MYL2

SGCD

VCL

CSRP3

MYL3

SURF1

DES

MYPN

TAZ

EMD

NEBL

TCAP
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152 children, 6 (4%) declined to receive genetic results.
A positive result was defined as ≥1 pathogenic or likely
pathogenic variants known to cause cardiomyopathy in
children. Results that confirmed previous clinical testing
results were not returned to participants; thus, only new
positive findings were returned.
Filtering was performed (single-nucleotide polymorphism database 144, minor allele frequency <5%) at
low stringency to retain potential modifying variants
for future studies. Retained variants were predicted
to alter the protein (missense, frameshift, insertion/deletion, stop gained or lost, and splice-site mutations).
Because of the large number of variants in the TTN
gene encoding the protein titin and good evidence for
truncating variants in TTN causing DCM, only nonsense and frameshift variants located within the A-
band region of the protein were interpreted.25,26
For all 37 genes, potential protein-
altering rare
variants were interpreted according to the American
College of Medical Genetics and Genomics standards
and guidelines for the interpretation of sequence variants to assess pathogenicity27 (Table S4). All variant
interpretations were concordant with ClinVar (https://
www.ncbi.nlm.nih.gov/clinv
ar/) as of December 1,
2018. Variants were interpreted as pathogenic, likely
pathogenic, VUS, likely benign, or benign (Table S4).
All novel variants are being deposited into ClinVar.
Downloaded from http://ahajournals.org by on September 13, 2021

Statistical Analysis
Categorical variables are summarized with frequencies, and age at diagnosis is summarized with medians with interquartile ranges. To identify differences
between the cardiomyopathy phenotypes, we first
combined LVNC and mixed phenotypes because of
the small sample size for each group (3 and 13, respectively). Fisher’s exact test and chi-
squared test
were used to assess associations between phenotype

and categorical variables, and the Wilcoxon rank sum
test (given the non-normal distribution) was used to assess age at diagnosis and enrollment.
To identify factors associated with the decision to
undergo clinical genetic testing, we used contingency
tables, chi-squared, or Fisher’s exact tests, as appropriate, for categorical variables (sex, race/ethnicity [races
from East Asian or South Asian superpopulations or
non-Hispanic White ethnicity], family history) and the
Wilcoxon rank-sum test for age at diagnosis and enrollment. To evaluate whether factors independently
contributed, logistic regression was performed, with
performance of clinical genetic testing as the dependent variable and age at diagnosis, sex, race/ethnicity,
family history, and cardiomyopathy type as predictor
variables. Chi-squared tests evaluated whether cardiomyopathy phenotype was associated with positive genetic findings in children with clinical test results. Alpha
was set at 0.05 and all tests were 2-tailed. Significance
thresholds were not adjusted for multiplicity. Data were
analyzed with JMP v13.1.0 (SAS Institute, Cary, NC).

RESULTS
PCM Genes Participants
Demographics for the first 152 probands enrolled in
the PCM Genes, representing 9 of the 14 participating sites, are shown in Table 2. The cohort was 51%
male and predominantly non-Hispanic White. Median
age (interquartile range) at diagnosis was 4.5 (0.5–13.2)
years (Table 2). Median age (interquartile range) at enrollment was 10.5 (3.3–15.7) years. The ratio of DCM
to HCM was about 2:1, which is consistent with other
epidemiologic studies6,8,20,26-29 (Figure 1). Children with
RCM represented 9% of the cohort, slightly higher than
the reported frequency of 5% among all cardiomyopathies.30 Three children (2%) had isolated LVNC, and 13

Table 2. Characteristics of Children With Cardiomyopathy in the Pediatric Cardiomyopathy Genes Study, by Phenotype
Type of Cardiomyopathy

Characteristic
Male, %

Restrictive,
n=14

Left Ventricular
Noncompaction/
Mixed, n=16

All, N=152

Dilated, n=80

Hypertrophic,
n=42

51.3

43.8

71.4

42.9

43.8

Race/ethnicity, %
White

73.7

66.3

90.5

78.6

62.5

Black

13.2

16.3

4.8

7.1

25.0

East Asian, South Asian

13.2

17.5

4.8

14.3

12.5

81.6

83.8

83.3

78.6

68.8

Median (IQR) age at diagnosis, y

Non-Hispanic

4.5 (0.5–13.2)

1.9 (0.3–11.1)

12.0 (6.0–15.0)

9.7 (1.0–14.4)

0.84 (0.09–8.5)

Median (IQR) age at enrollment, y

11.2 (4.8–16.8)

10.5 (3.3–15.7)

16.1 (10.1–18.8)

11.9 (4.5–17.7)

5.3 (2.0–9.1)

2.7 (0.5– 6.9)

3.8 (0.6–7.6)

3.0 (0.5–7.6)

2.2 (1.0–2.9)

1.4 (0.4–3.5)

40.8

28.8

66.7

28.6

43.8

Median (IQR) time from diagnosis to enrollment, y
Family history, % positive
IQR indicates interquartile range.
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Figure 1. Characteristics of 152 children in the pediatric cardiomyopathy genes
study.
A, Distribution of cardiomyopathy phenotypes; B, Median (interquartile range) age at
cardiomyopathy diagnosis by sex and cardiomyopathy phenotype. DCM indicates
dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left ventricular
noncompaction; and RCM, restrictive cardiomyopathy.

(9%) had a mixed phenotype that frequently included
LVNC (9/13; 69%).

Differences by Cardiomyopathy
Phenotype
Age at diagnosis differed significantly between the
cardiomyopathy phenotypes (P<0.0001; Table 2 and
Figure 1). These differences were largely driven by the
higher median age at diagnosis for HCM than for DCM
(P<0.0001) and LVNC/Mixed (P=0.0004). The phenotypes also differed by sex (P=0.02), with HCM having
more males (71%) than the other phenotypes, and by
race or ethnicity (P=0.02), with HCM and RCM having higher proportions of non-Hispanic White individuals (81% and 71%, respectively) than DCM and LVNC/
Mixed (58% and 44%, respectively). Children with HCM
had the highest frequency of a positive family history
(67%), with DCM and RCM each having 29% (P<0.001).

Clinical Genetic Testing Practices and
Outcomes
Figure 2 shows the proportion of patients who underwent clinical genetic testing. Overall, 89 children (59%)

had results available at the time of exome analysis.
Of these, 81 (53%) had a cardiomyopathy gene panel,
and another 8 had other genetic testing (targeted testing for a known familial variant [6], exome testing [1],
and unspecified cardiomyopathy genetic testing [1]).
These 8 children were excluded when the frequency
and yield of clinical panel testing was calculated
(Figure 2).
We evaluated factors associated with cardiomyopathy gene panel testing between those who did and
did not have previous clinical test results (Table 3).
Children who had undergone testing had a higher rate
of positive family history (51% versus 22%; P=0.005).
Age of enrollment, sex, and race were not associated
with clinical genetic testing, but cardiomyopathy phenotype was (P=0.03; Figure 2). Specifically, children
with HCM were more likely than children with DCM to
undergo clinical testing (74% versus 46%, P=0.005). In
a logistic regression model, only family history retained
significance (OR=3.1 [1.4–6.8]; P=0.0044). The lack of
significance for type of CM was likely attributable to the
strong association between type of cardiomyopathy
and family history with HCM having a much higher rate
of positive family history than DCM (67% versus 29%,

J Am Heart Assoc. 2021;10:e017731. DOI: 10.1161/JAHA.120.0177315

The Pediatric Cardiomyopathy Genes Study

80

80

70

70

60

60

50

50

Percent

Percent

Ware et al

40
30

40
30

20

20

10

10

0

0
DCM
(n=78)

HCM
(n=38)

RCM
(n=13)

LVNC/Mixed
(n=15)

Phenotype

Downloaded from http://ahajournals.org by on September 13, 2021

Sequencing Results
Of the variants reported for children who had already
undergone clinical testing, 89% were also identified
Table 3. Factors Associated With Clinical Genetic Testing
in Children With a Cardiomyopathy Diagnosis
Clinical Genetic Testing

Median (IQR) age at diagnosis, y

No, n=63

5.5 (0.7–13.2) 2.9 (0.4–13.2)

P Value
0.59

Male, %

49.4

49.2

0.98

Race, non-Hispanic White, %

65.4

58.7

0.41

Family history, % positive

50.6

22.2

0.005

Hypertrophic

34.6

15.9

Dilated

44.4

66.7

Restrictive

8.6

9.5

Left ventricular
noncompaction/mixed

12.4

7.9

Cardiomyopathy type, %

RCM
(n=7)

LVNC/Mixed
(n=10)

VUS

Figure 3. Clinical genetic testing results in 81 cardio
myopathy patients by phenotype.
Results interpreted as pathogenic or likely pathogenic are
considered positive. Patients who did not have cardiomyopathy
panel testing were excluded. DCM indicates dilated
cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVNC, left
ventricular noncompaction; RCM, restrictive cardiomyopathy;
and VUS, variant of uncertain significance.

respectively; P<0.0001). Variation across the sites was
marked (Figure S1). Of sites contributing at least 10
cases, 3 sites performed testing in less than one-third
of children (range, 19%–32%), 1 site performed testing
in about half (47%), and 3 sites performed testing in at
least two-thirds of children (range, 68%–97%).
Of 81 children who underwent clinical cardiomyopathy gene panel testing, 39 (48%) had a positive
result; 19 (24%) had a VUS as the primary finding;
and 23 (28%) had negative genetic testing results
(Figure 3). Overall, the frequency of positive results
was higher in children with HCM (68%) than with DCM
(31%; P=0.0008).

Yes*, n=81

HCM
(n=28)
Positive

Figure 2. Frequency of clinical genetic
cardiomyopathy panel testing by cardio
myopathy subtype.
DCM indicates dilated cardiomyopathy;
HCM, hypertrophic cardiomyopathy; LVNC,
left ventricular noncompaction; and RCM,
restrictive cardiomyopathy.

Factor

DCM
(n=36)

0.03

IQR indicates interquartile range.
*Eight children with genetic testing other than cardiomyopathy panel
testing (eg, testing for known familial variant) were excluded.

by exome sequencing, with indel variants in TTN accounting for most of the variants missed by exome.
In the 63 children who had not previously undergone
clinical genetic testing, a group predicted to have
a lower diagnostic yield because of the increased
number of children with DCM and children without
a family history of disease, 21% (13/63) had an identifiable pathogenic or likely pathogenic variant. Four
had DCM, 6 had HCM, 2 had RCM, and 1 had LVNC/
Mixed. Of these 13 children, 12 had a single variant
identified as pathogenic or likely pathogenic, and 1
child had 2 variants.
Based on exome sequencing of 37 known cardiomyopathy genes, 32% (49/152) had a positive pathogenic or likely pathogenic finding. Five children (3%)
had 2 pathogenic or likely pathogenic variants; no child
had >2. Positive results (Table S4) differed by cardiomyopathy type and family history (Figure 4). Diagnostic
yields for familial DCM, HCM, RCM, and LVNC/Mixed
cases were 35%, 68%, 75%, and 43%, respectively.
Although idiopathic cases of HCM or RCM also had
high diagnostic yields of 36% and 50%, respectively,
idiopathic DCM cases tested positive less frequently
(9%). None of the 3 children with isolated LVNC had
positive findings, although 2 of the 3 had a positive
family history of cardiomyopathy.

Cardiac Surveillance and Genetic Testing
in Family Members
Cardiac surveillance in first-degree relatives of a child
with cardiomyopathy is recommended. Similarly, predictive genetic testing is indicated in first-degree relatives of those with a pathogenic or likely pathogenic
variant. Among our patients with a positive family history of cardiomyopathy, 89% (55/72 familial cases) had
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Figure 4. Frequency of positive exome testing results in
children with cardiomyopathy by phenotype and family
history status.
DCM indicates dilated cardiomyopathy; HCM, hypertrophic
cardiomyopathy; LVNC, left ventricular noncompaction; and
RCM, restrictive cardiomyopathy.
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cardiac surveillance in first-degree relatives, whereas
in those without a family history, 42% (38/90 idiopathic
cases) had cardiac surveillance of first-
degree relatives. When focusing on the subset of probands who
did not have clinical genetic testing (n=63), 10 of 14
familial cases (71%) had cardiac imaging in first-degree
relatives, whereas 16 of 49 idiopathic cases (41%) had
cardiac screening in first-degree relatives. Overall, predictive genetic testing was performed in 58% of first-
degree relatives of familial cases. In probands with
no documented family history who underwent clinical
genetic testing, 3 had presumed de novo pathogenic
variants (both parents documented as negative for the
pathogenic variant), 4 had VUS results that were inherited from an unaffected parent, and 1 had clinical
exome testing performed as a quad test with mother,
father, and brother, which was negative. Of note, this
study was not longitudinal in nature and therefore additional family members may have undergone cardiac
screening or predictive genetic testing since study
enrollment. Importantly, 77% (10/13) of children with
positive exome results who had not previously had
clinical testing also had no family history of disease.
For the entire cohort, the 14 children with new positive
molecular findings had 44 at-risk first-degree relatives
(parents and siblings).

DISCUSSION
We conducted a multicenter study to better understand the genetic basis of familial and idiopathic
pediatric cardiomyopathy. Information collected on
152 children provided important new data about clinical genetic testing practices in North America. With
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research sequencing on 152 children, we identified
minimum diagnostic yields in known cardiomyopathy
genes for broadly inclusive genetic testing in children
with either familial or idiopathic cardiomyopathy.
Previous studies of the PCMR have provided information on the epidemiologic features and clinical
outcomes of children with cardiomyopathy or heart
failure,8,22,29-32 and an understanding of the causal
categories7,33,34 and their impact on risk stratification
and outcome,32,35-37 but information on genetic causes
specifically in the pediatric population has been limited. The PCM Genes study was intended to establish
disease-
specific genotype-
phenotype correlations in
pediatric cardiomyopathy and to provide a more sophisticated understanding of the molecular basis of
disease and its association with presentation, clinical
course, and outcome.
Another PCMR study8 found that 51% of children
had a diagnosis of DCM, a finding similar to the 53%
(80/152) of our cohort. However, HCM (n=42) was less
common in our cohort (28% versus 42%), and, as anticipated, this group had the highest proportion of children with positive family histories of cardiomyopathy.
Somewhat surprisingly, the frequency of family history
of cardiomyopathy in the LVNC/Mixed cardiomyopathy
group was 44% (7/16). Two recent publications recommend genetic testing when HCM or DCM is seen in
conjunction with LVNC and do not recommend testing for isolated LVNC in the absence of a family history.3,38 An additional publication of LVNC patients of
all ages that included 52 patients <18 years of age also
found a low genetic diagnostic yield in sporadic cases
of isolated LVNC and determined that left ventricular
systolic dysfunction at presentation and long-
term
outcome were related to genetics.39 All positive cases
in our LVNC/Mixed group would have been identified
clinically following these guidelines. However, with only
16 children, our LVNC/Mixed group was small, and additional studies are required to better understand the
genetic basis of mixed cardiomyopathy phenotypes.
Our results show that although genetic testing is
being widely used it is not yet universal, and variations in practice are great. The frequency of testing
ranged from none to 97% of patients. In previous
studies, factors influencing decisions to order or
recommend genetic testing have included perceived ability to obtain testing, knowledge and comfort level with understanding and discussing results,
and perception of benefits or clinical utility.40-42 At
the time of study initiation, no clinical guidelines existed that specifically recommended genetic testing
for cardiomyopathy in children, which may account
for some of the variability. The availability and integration of geneticist and genetic counselor expertise
as well as the cardiologists’ acceptance of the importance of cardiac genetics may also have played
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roles, although this study was not designed to assess this directly. A recent study has shown that genetic testing is less used in index patients with HCM
than in long QT syndrome.43 At-r isk first-degree
family members of a child with cardiomyopathy or
long QT syndrome are more likely to participate in
recommended cardiac screening than genetic testing,5,43 although screening participation was higher
in families of gene-positive children. In the current
study, family history status and cardiomyopathy type
were significantly associated with performing testing. However, family history status is at least partially
dependent on comprehensive cardiac surveillance
in first-degree relatives. First-degree relatives underwent cardiac screening in 42% of idiopathic cases,
potentially leading to an underestimation of the prevalence of familial disease in affected asymptomatic
family members. In the field of cardiovascular genetics, barriers to cardiac screening or genetic testing
centered on patient concerns have not been well
studied, but at least 1 study suggests that family
decisions are more frequently the cause than insurance.43 Further studies investigating motivation and
barriers to genetic testing in children with cardiomyopathy will be necessary to delineate provider-and
family-specific factors.
We identified pathogenic or likely pathogenic variants
in 32% of children (49/152). Among tested patients, HCM
and RCM both had a high diagnostic yield and a low
frequency of VUS. Because RCM is quite rare, yields of
genetic testing have not been widely reported, although
a 2008 study previously reported 4 of 12 RCM patients
with mutations in sarcomeric genes including TNNI3,
ACTC, and TNNT2.44 In this study, 8 of 14 (57%) had
pathogenic or likely pathogenic variants identified, suggesting that more widespread use of testing in this population should be considered. In contrast, the positive
and VUS frequencies were nearly equal in children with
DCM and LVNC/Mixed phenotypes, perhaps reflecting
a greater genetic heterogeneity in these subtypes. Of 63
children without previous genetic testing, positive results
were identified in 13 (21%), as well as in 1 child whose
previous test results were negative. These missed opportunities for a molecular diagnosis by clinical testing have
important implications for first-degree relatives for whom
targeted familial testing can be offered, allowing risk
stratification and targeted cascade screening. Ongoing
cardiac surveillance is indicated in first-degree relatives
of a child with cardiomyopathy when the cause is unknown.2-4 For these 14 families with a new molecular diagnosis, testing for the known familial pathogenic variant
in the 44 first-degree relatives can identify individuals who
require ongoing surveillance and those who do not and is
cost-effective by limiting ongoing evaluations and cardiac
imaging to at-risk family members.15,45 Importantly, these
missed genetic diagnoses occurred across all types of
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cardiomyopathy, indicating that all functional phenotypes
of pediatric cardiomyopathy have a potential molecular
cause identifiable through genetic testing.
A family history of cardiomyopathy indicates a genetic cause, and therefore it was not surprising to find
a significant association with clinical genetic testing in
this study. Interestingly, we also identified pathogenic
genetic variants in 36% of children with idiopathic HCM
and 50% of children with idiopathic RCM. Although
DCM typically has a lower diagnostic yield than that in
other types of cardiomyopathy (20%–30%), we found
that 35% with familial DCM had positive results. In idiopathic DCM, the rate was lower (9%). Nevertheless,
reclassifying 9% of idiopathic DCM cases as heritable
substantially alters the care for family members. Thus,
family history status may be useful to estimate prior
probability of a positive genetic test but cannot be
used to rule out the need for genetic testing. Overall,
our results support use of genetic testing in cases of
both familial and idiopathic cardiomyopathy.

Strengths and Limitations of the Study
Children were enrolled at centers with known expertise in
pediatric cardiomyopathy; therefore, we cannot exclude
ascertainment bias for more severe or atypical cases. All
eligible patients with cardiomyopathy were approached,
but we cannot completely eliminate the possibility of a
survivor bias. This study was not longitudinal in nature
and family history is dynamic. Cardiac surveillance and
predictive cascade clinical genetic testing in family members may have occurred on a clinical basis after study
data capture. Because we tested for 37 known cardiomyopathy genes, the diagnostic yield for each phenotype should be viewed as a minimum estimate.
Variant interpretation continues to be a challenge
in clinical genetics.46-48 Recent studies on HCM have
called for more stringent interpretation especially in research studies.15,49,50 We interpreted variants conservatively using currently accepted American College of
Medical Genetics and Genomics guidelines.27 A subset of VUS identified in this study may be upgraded to
likely pathogenic or pathogenic variants with further
investigation with family-
based segregation studies,
which were not performed in this proband only study.
New approaches to better predict variant effects are
needed to increase their clinical utility and are particularly important in the context of autosomal dominant
diseases such as cardiomyopathy. Our results indicate
that additional genetic causes remain to be discovered
in pediatric cardiomyopathy.

CONCLUSIONS
Our study highlights that a definitive molecular genetic
diagnosis can be made in a substantial proportion of
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children for whom the cause and heritable nature of their
cardiomyopathy have been previously unknown. Overall,
our results support use of genetic testing in cases of
both familial and idiopathic cardiomyopathy. The diagnostic yields of genetic testing we found can serve as
minimum yields for future studies. Additional genetic
causes of pediatric cardiomyopathy remain to be discovered. The wide variation in genetic testing practices
should be addressed, and improvements can be made
in comprehensive cardiac screening and predictive genetic testing in first-degree relatives. Barriers to genetic
testing for pediatric cardiomyopathy should be identified
and removed to make testing more widely available.
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Table S1. Echocardiography criteria for study eligibility.
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Measurements: (At least 2 must be present at the time of CM diagnosis
for the patient to be eligible, unless otherwise noted)
1) Left ventricular fractional shortening or ejection fraction >2 s.d. below the
normal mean for age. Fractional shortening is acceptable in patients with
normal ventricular configuration and no regional wall motion abnormalities.
Abnormal ejection fraction by echocardiography, radionuclide or contrast
angiography, or MRI are acceptable alternatives, but age-appropriate norms
for the individual laboratory must be employed.
2) Left ventricular posterior wall or septal thickness at end-diastole >3 s.d.
above the normal mean for body-surface area. (This criterion applies to HCM
only; Meeting this single criterion qualifies the patient as eligible)
3) Left ventricular end-diastolic posterior wall thickness-to- end-diastolic
dimension ratio <0.12.
4) Left ventricular end-diastolic dimension or volume > 2 s.d. above the normal
mean for body-surface area. Dimension data are acceptable under the
conditions outlined in Measurement Criteria 1 for fractional shortening, and
volume data may be derived from the imaging methods as in Measurement
Criterion 1.
Patterns: (At least 1 must be met for the patient to be eligible if
Measurement criteria are not met at the time of CM diagnosis)
1) Localized ventricular hypertrophy, such as septal thickness >1.5 x left
ventricular posterior wall thickness with at least normal left ventricular posterior
wall thickness, with or without dynamic outflow obstruction.
2) Restrictive cardiomyopathy: one or both atria enlarged relative to ventricles
of normal or small size with evidence of impaired diastolic filling and in the
absence of significant valvular heart disease.
3) Contracted form of endocardial fibroelastosis, similar to restrictive
cardiomyopathy plus echo-dense endocardium.
4) Ventricular dysplasia/Uhl’s anomaly: very thin right ventricle with dilated right
atrium usually better assessed by MRI than echo.
5) Left ventricular myocardial noncompaction: very trabeculated spongiform left
ventricular myocardium with multiple interstices.

Table S2. Inclusion and exclusion criteria.

Inclusion criteria:
1) Patient is alive
A. Patients who are status-post heart transplant are eligible if pre-transplant
longitudinal data is available.
2) Under age 18 years of age at the time of the diagnosis.
3) Either primary or idiopathic Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy,
Restrictive Cardiomyopathy, or Left Ventricular Noncompaction.
4) A diagnosis of cardiomyopathy which, at the time of diagnosis, was confirmed by:
● Echocardiographic criteria, OR
● Cardiac MRI
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Exclusion criteria:
Arrhythmogenic right ventricular dysplasia

Neuromuscular disease (defined by the specific conditions listed in Appendix A)

Endocrine disease known to cause heart muscle disease (including infants of diabetic mothers)

History of rheumatic fever

Toxic exposures known to cause heart muscle disease (anthracyclines, mediastinal radiation,
iron overload, or heavy metal exposure)

HIV infection or born to an HIV positive mother

Kawasaki disease

Immunologic disease

Invasive cardiothoracic procedures or major surgery during the preceding month, except those
specifically related to cardiomyopathy including LVAD, ECMO, and AICD placement
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Uremia, active or chronic

Abnormal ventricular size or function that can be attributed to intense physical training or
chronic anemia

Chronic arrhythmia, unless there are studies documenting inclusion criteria prior to the onset
of an arrhythmia (except a patient with a chronic arrhythmia, subsequently ablated, whose
cardiomyopathy persists after two months is not to be excluded)

Malignancy

Systemic hypertension

Pulmonary parenchymal or vascular disease (e.g., cycstic fibrosis, cor pulmonale, or
pulmonary hypertension)

Ischemic coronary vascular disease

Association with drugs known to hypertrophy (e.g., growth hormone, corticosteroids, cocaine)

Genetic syndrome or chromosomal abnormality known to be associated with cardiomyopathy
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Table S3. Exome sequencing metrics. See Excel file.

Table S4. Variants identified in 37 clinically relevant genes. See Excel file.
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Figure S1. Variation across the sites.
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